{"id":10377,"date":"2026-06-30T10:41:44","date_gmt":"2026-06-30T02:41:44","guid":{"rendered":"https:\/\/regask.com\/?p=10377"},"modified":"2026-06-30T10:41:44","modified_gmt":"2026-06-30T02:41:44","slug":"acces-au-marche-des-medicaments-et-tarification-juin-2026","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/drug-pricing-market-access-june-2026\/","title":{"rendered":"Prix des m\u00e9dicaments et acc\u00e8s au march\u00e9 en 2026\u00a0: Medicare Neg\u2026"},"content":{"rendered":"<p id=\"ember1956\" class=\"ember-view reader-text-block__paragraph\"><span class=\"TextRun SCXW232482172 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><strong><span class=\"NormalTextRun SCXW232482172 BCX0\">La tarification des m\u00e9dicaments et l&#039;acc\u00e8s au march\u00e9 sont pass\u00e9s \u00e0\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW232482172 BCX0\">centre<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">\u00a0de la r\u00e9glementation pharmaceutique \u00e0 la mi-2026, l&#039;accent \u00e9tant mis sur le financement plut\u00f4t que sur l&#039;enregistrement<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">,<\/span><\/strong><span class=\"NormalTextRun SCXW232482172 BCX0\"><strong>\u00a0Tarification, financement et \u00e9valuation des technologies de la sant\u00e9.<\/strong> Les \u00c9tats-Unis ont fait progresser leur cadre de n\u00e9gociation des prix de Medicare, l&#039;Espagne a lanc\u00e9 une consultation sur le prix des m\u00e9dicaments et le Portugal\u00a0<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">formalis\u00e9<\/span><span class=\"NormalTextRun SCXW232482172 BCX0\">\u00a0Un r\u00e9gime national d&#039;\u00e9valuation des technologies de la sant\u00e9, le tout en un seul mois. C&#039;est \u00e0 ce stade du cycle de vie qu&#039;un produit parfaitement approuvable peut malgr\u00e9 tout \u00e9chouer sur le plan commercial, et l&#039;\u00e9cart entre l&#039;approbation et l&#039;acc\u00e8s au march\u00e9 se creuse.<\/span><\/span><span class=\"EOP Selected SCXW232482172 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n\t<div id=\"gap-256462775\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-256462775 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h3><strong><span class=\"TextRun MacChromeBold SCXW167568299 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW167568299 BCX0\">Les \u00c9tats-Unis ont \u00e9largi la n\u00e9gociation des prix des m\u00e9dicaments de Medicare.<\/span><\/span><\/strong><\/h3>\n\t<div id=\"gap-101110179\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-101110179 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"NormalTextRun SCXW16343997 BCX0\">Les Centers for Medicare &amp; Medicaid Services ont publi\u00e9 un projet de r\u00e9glementation concernant le programme de n\u00e9gociation des prix des m\u00e9dicaments de Medicare et le plan de paiement des ordonnances de Medicare. La n\u00e9gociation des prix a profond\u00e9ment transform\u00e9 la planification commerciale aux \u00c9tats-Unis depuis son introduction, et chaque extension \u00e9largit le champ d&#039;application de la n\u00e9gociation des prix.\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">produits,<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0et le\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">m\u00e9canique&#039;\u2019<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0Les fabricants doivent d\u00e8s maintenant \u00e9laborer des mod\u00e8les\u00a0: strat\u00e9gie de prix, s\u00e9quence de lancement et planification du cycle de vie.\u00a0<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">doit<\/span><span class=\"NormalTextRun SCXW16343997 BCX0\">\u00a0Il faut tenir compte du risque de n\u00e9gociation au lieu de le consid\u00e9rer comme un cas marginal. Les entreprises qui s&#039;adaptent en premier int\u00e8grent des sc\u00e9narios de n\u00e9gociation dans leurs pr\u00e9visions\u00a0; les autres voient leurs hypoth\u00e8ses se r\u00e9v\u00e9ler erron\u00e9es.<\/span><\/p>\n<h3><strong><span class=\"TextRun MacChromeBold SCXW86240589 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW86240589 BCX0\">L&#039;Espagne a progress\u00e9 dans sa r\u00e9forme des prix et du financement<\/span><\/span><\/strong><\/h3>\n\t<div id=\"gap-1765946274\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1765946274 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"NormalTextRun SCXW22514267 BCX0\">Le minist\u00e8re espagnol de la Sant\u00e9 a lanc\u00e9 une consultation publique sur un projet de d\u00e9cret royal visant \u00e0 moderniser le syst\u00e8me de tarification et de financement des m\u00e9dicaments. Ces consultations sur la r\u00e9forme des prix repr\u00e9sentent autant une opportunit\u00e9 qu&#039;un risque.\u00a0<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">(<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">la fen\u00eatre d&#039;opportunit\u00e9 pour s&#039;engager avant que les r\u00e8gles ne se durcissent<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">)<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">, mais<\/span><span class=\"NormalTextRun SCXW22514267 BCX0\">\u00a0Ces mesures indiquent \u00e9galement que les crit\u00e8res de remboursement sont r\u00e9ajust\u00e9s. Les entreprises pr\u00e9sentes sur le march\u00e9 espagnol ou souhaitant s&#039;y implanter devraient examiner attentivement le projet, mod\u00e9liser les implications financi\u00e8res et profiter de la p\u00e9riode de consultation pour pr\u00e9senter leurs arguments. S&#039;engager d\u00e8s maintenant est bien moins co\u00fbteux qu&#039;une r\u00e9vision des prix a posteriori.<\/span><\/p>\n<h3><strong><span class=\"NormalTextRun SCXW80489494 BCX0\">Portugal\u00a0<\/span><span class=\"NormalTextRun SCXW80489494 BCX0\">\u00e9tabli<\/span><span class=\"NormalTextRun SCXW80489494 BCX0\">\u00a0un cadre national d&#039;\u00e9valuation des technologies de la sant\u00e9<\/span><\/strong><\/h3>\n\t<div id=\"gap-1194914705\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1194914705 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW253334816 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW253334816 BCX0\">Le Portugal a publi\u00e9 le d\u00e9cret-loi 118\/2026\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00e9tablissement<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0un r\u00e9gime national d&#039;\u00e9valuation des technologies de la sant\u00e9,\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">formaliser<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0Comment les nouveaux m\u00e9dicaments et technologies sont \u00e9valu\u00e9s en vue de leur remboursement. L&#039;\u00e9valuation des technologies de la sant\u00e9 (ETS) est de plus en plus la v\u00e9ritable porte d&#039;entr\u00e9e vers l&#039;acc\u00e8s aux m\u00e9dicaments en Europe\u00a0: l&#039;autorisation de mise sur le march\u00e9 conf\u00e8re un droit \u00e0 remboursement.\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">licence<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">, mais c&#039;est HTA qui d\u00e9cide si le syst\u00e8me prend en charge les frais.\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">formalis\u00e9<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0ce cadre implique une structure plus pr\u00e9coce et plus structur\u00e9e\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">preuve de<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">demandes;<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">\u00a0<\/span><span class=\"NormalTextRun SCXW253334816 BCX0\">Les donn\u00e9es m\u00e9dico-\u00e9conomiques et l&#039;efficacit\u00e9 comparative doivent \u00eatre int\u00e9gr\u00e9es d\u00e8s la phase de d\u00e9veloppement, et non pas rassembl\u00e9es au moment du lancement lorsque le protocole d&#039;essai et les comparateurs sont d\u00e9j\u00e0 fix\u00e9s.<\/span><\/span><span class=\"EOP SCXW253334816 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>\n<h3><strong><span class=\"NormalTextRun SCXW227434142 BCX0\">Quoi\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW227434142 BCX0\">ce<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">\u00a0<\/span><span class=\"NormalTextRun ContextualSpellingAndGrammarErrorV2Themed SCXW227434142 BCX0\">moyens<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">\u00a0pour\u00a0<\/span><span class=\"NormalTextRun SCXW227434142 BCX0\">pharmaceutique<\/span><\/strong><\/h3>\n\t<div id=\"gap-856334140\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-856334140 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun SCXW97054545 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW97054545 BCX0\">Aux \u00c9tats-Unis, en Espagne et au Portugal, le message est clair : obtenir l&#039;approbation n&#039;est plus le plus difficile.<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">,\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00eatre pay\u00e9, c&#039;est... Apportez\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">acc\u00e8s au march\u00e9<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0Anticiper l&#039;avenir. Se familiariser avec les techniques de n\u00e9gociation de prix aux \u00c9tats-Unis et participer \u00e0 des consultations en mati\u00e8re de prix comme en Espagne.\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">ils sont<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0ouvrir et constituer rapidement des preuves de niveau HTA pour les march\u00e9s\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">formaliser<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0\u00e9valuation. La strat\u00e9gie d&#039;acc\u00e8s fait d\u00e9sormais partie int\u00e9grante de la planification du d\u00e9veloppement, au m\u00eame titre que le programme clinique.<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">m<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">, pas dans la ru\u00e9e post-approbation o\u00f9\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">preuve de<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0options\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">a<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0d\u00e9j\u00e0 r\u00e9duit.\u00a0<\/span><strong><a href=\"http:\/\/regask.com\/fr\/\"><span class=\"NormalTextRun SpellingErrorV2Themed SCXW97054545 BCX0\">RegASK<\/span><\/a><\/strong><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0surveille l&#039;\u00e9volution des prix, des remboursements et des \u00e9valuations des technologies de la sant\u00e9 sur les march\u00e9s mondiaux, en aidant les \u00e9quipes r\u00e9glementaires et d&#039;acc\u00e8s au march\u00e9.\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">plan<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">\u00a0barri\u00e8res d&#039;acc\u00e8s avant\u00a0<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">lancement<\/span><span class=\"NormalTextRun SCXW97054545 BCX0\">.<\/span><\/span><span class=\"EOP SCXW97054545 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:0,&quot;335559739&quot;:0}\">\u00a0<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Drug pricing and market access moved to the\u00a0centre\u00a0of pharma regulation in mid-2026, as the focus shifted from registration to money,\u00a0pricing, financing, and health technology assessment. The US advanced its Medicare price-negotiation framework, Spain opened a consultation on drug pricing, and Portugal\u00a0formalized\u00a0a national HTA regime, all in the same month. This is the part of the&#8230;<\/p>","protected":false},"author":46,"featured_media":10378,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10377","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.8 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Drug Pricing and Market Access Explained in 2026<\/title>\n<meta name=\"description\" content=\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/acces-au-marche-des-medicaments-et-tarification-juin-2026\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug Pricing &amp; Market Access in 2026: Medicare Negotiation, Spain Reform &amp; Portugal HTA\" \/>\n<meta property=\"og:description\" content=\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/acces-au-marche-des-medicaments-et-tarification-juin-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T02:41:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Shaffa Renaningtyas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaffa Renaningtyas\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"},\"author\":{\"name\":\"Shaffa Renaningtyas\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\"},\"headline\":\"Drug Pricing &#038; Market Access in 2026: Medicare Neg&hellip;\",\"datePublished\":\"2026-06-30T02:41:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"},\"wordCount\":490,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"articleSection\":[\"Blogs\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\",\"name\":\"Drug Pricing and Market Access Explained in 2026\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"datePublished\":\"2026-06-30T02:41:44+00:00\",\"description\":\"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/drug-pricing-market-access-june-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png\",\"width\":800,\"height\":600,\"caption\":\"Drug Pricing & Market Access In 2026 Medicare Negotiation, Spain Reform & Portugal Hta\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/6d86c29c9123b2b67a3ea8e259cdb925\",\"name\":\"Shaffa Renaningtyas\",\"sameAs\":[\"https:\\\/\\\/regask.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Explication de la tarification des m\u00e9dicaments et de l&#039;acc\u00e8s au march\u00e9 en 2026","description":"Explorez les enjeux li\u00e9s \u00e0 la fixation des prix des m\u00e9dicaments et \u00e0 l&#039;acc\u00e8s au march\u00e9 dans un contexte r\u00e9glementaire en constante \u00e9volution. Comprenez l&#039;impact sur la commercialisation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/acces-au-marche-des-medicaments-et-tarification-juin-2026\/","og_locale":"fr_FR","og_type":"article","og_title":"Drug Pricing & Market Access in 2026: Medicare Negotiation, Spain Reform & Portugal HTA","og_description":"Explore the challenges of drug pricing and market access in a changing regulatory landscape. Understand the impact on commercialization.","og_url":"https:\/\/regask.com\/fr\/acces-au-marche-des-medicaments-et-tarification-juin-2026\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-06-30T02:41:44+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","type":"image\/png"}],"author":"Shaffa Renaningtyas","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Shaffa Renaningtyas","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#article","isPartOf":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"},"author":{"name":"Shaffa Renaningtyas","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925"},"headline":"Drug Pricing &#038; Market Access in 2026: Medicare Neg&hellip;","datePublished":"2026-06-30T02:41:44+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"},"wordCount":490,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","articleSection":["Blogs"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/","url":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/","name":"Explication de la tarification des m\u00e9dicaments et de l&#039;acc\u00e8s au march\u00e9 en 2026","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","datePublished":"2026-06-30T02:41:44+00:00","description":"Explorez les enjeux li\u00e9s \u00e0 la fixation des prix des m\u00e9dicaments et \u00e0 l&#039;acc\u00e8s au march\u00e9 dans un contexte r\u00e9glementaire en constante \u00e9volution. Comprenez l&#039;impact sur la commercialisation.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/drug-pricing-market-access-june-2026\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/drug-pricing-market-access-june-2026\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/06\/drug-pricing-market-access-in-2026_-medicare-negotiation-spain-reform-portugal-hta.png","width":800,"height":600,"caption":"Drug Pricing & Market Access In 2026 Medicare Negotiation, Spain Reform & Portugal Hta"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/6d86c29c9123b2b67a3ea8e259cdb925","name":"Shaffa Renaningtyas","sameAs":["https:\/\/regask.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/10377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/46"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=10377"}],"version-history":[{"count":3,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/10377\/revisions"}],"predecessor-version":[{"id":10381,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/10377\/revisions\/10381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/10378"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=10377"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=10377"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=10377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}